NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
Every great story has memorable characters, but not all of them play the same role. While the protagonist usually takes center stage, other key characters help shape the narrative in equally important ...
NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113), a first-in-class investigational targeted oral ...
The stock of Protagonist Therapeutics, Inc. has more than doubled so far this year due to progress on a couple of fronts. Can the rally in the shares continue in 2023? An updated investment analysis ...
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results